Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00689416 |
The primary aim of this study is to investigate the effect of 40 mg dose of rosuvastatin on carotid plaque inflammation measured with MRI and PET scanning, to evaluate whether these techniques are promising for future proof of principle studies. A number of patients will receive placebo as a control.
Condition | Intervention | Phase |
---|---|---|
Atherosclerosis Inflammatory Activity in Carotid Arteries |
Drug: rosuvastatin Drug: placebo |
Phase 0 |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment |
Official Title: | Exploratory Study of New Imaging Biomarkers for Measurement of Carotid Plaque Inflammation |
Estimated Enrollment: | 74 |
Study Start Date: | December 2007 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: rosuvastatin
40 mg, tablet, once daily for 3 months.
|
2: Placebo Comparator |
Drug: placebo
40 mg, tablet, once daily for 3 months
|
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca Clinical Study Information | + 46 31 776 10 00 | maria.eriksson-lepkowska@astrazeneca.com |
Sweden | |
Research Site | Recruiting |
Uppsala, Sweden |
Principal Investigator: | Håkan Ahlström, MD, Professor | Uppsala University Sweden |
Study Chair: | Maria Leonsson-Zachrissson, MD, Study Physician | AstraZeneca R&D Mölndal |
Responsible Party: | AstraZeneca R&D Mölndal, Sweden ( Björn Carlsson, MD, PhD, Medical Science Director, Discovery Medicine CDT ) |
Study ID Numbers: | D4411M00010 |
Study First Received: | May 30, 2008 |
Last Updated: | May 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00689416 |
Health Authority: | Sweden: Regional Ethical Review Board |
imaging biomarkers MRI FDG-PET/CT scanning Crestor |
Arterial Occlusive Diseases Atherosclerosis Rosuvastatin |
Vascular Diseases Arteriosclerosis Inflammation |
Antimetabolites Pathologic Processes Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Enzyme Inhibitors Cardiovascular Diseases Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |